Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Catalyst PharmaceuticalsCPRX +0.02%70 Cash Ratio is 5.71 as of Mar. 2026, which is 1% below its 10-year median of 5.75. GuruFocus rates CPRX with a GF Score™ of 70/100 and a GF Value™ of $25.01 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,379 Biotechnology companies, Catalyst Pharmaceuticals ranks better than 67.22% on this metric.
Catalyst Pharmaceuticals has a Cash Ratio of 5.71. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Catalyst Pharmaceuticals's Cash Ratio or its related term are showing as below:
CPRX'
s Cash Ratio Range Over the Past 10 Years
Min: 1.81 Med: 5.75 Max: 28.54
Current: 5.71
During the past 13 years, Catalyst Pharmaceuticals's highest Cash Ratio was 28.54. The lowest was 1.81. And the median was 5.75.
CPRX's Cash Ratio is ranked better than 67.22% of 1379
companies
in the Biotechnology industry
Industry Median: 2.97
vs CPRX: 5.71
Catalyst Pharmaceuticals (NAS:CPRX) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Catalyst Pharmaceuticals Cash Ratio Related Terms
Catalyst Pharmaceuticals Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Catalyst Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Catalyst Pharmaceuticals Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Catalyst Pharmaceuticals's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Catalyst Pharmaceuticals (CPRX) has a Cash Ratio of 5.71 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Catalyst Pharmaceuticals and its competitors. This is near median its historical median of 5.75. Over the past decade, Catalyst Pharmaceuticals' Cash Ratio has ranged from 1.81 to 28.54. According to the industry distribution chart, Catalyst Pharmaceuticals ranks #452 out of 1379 companies in the Biotechnology industry, placing it in the top 32.8%.
Is Catalyst Pharmaceuticals' Cash Ratio too high?
Catalyst Pharmaceuticals' current Cash Ratio of 5.71 is near median its 10-year median of 5.75. Over the past 10 years, this metric has ranged from a low of 1.81 to a high of 28.54. The Biotechnology industry median Cash Ratio is 2.97. Catalyst Pharmaceuticals' value of 5.71 is 92.3% above this industry median. Based on the distribution chart, Catalyst Pharmaceuticals ranks #452 out of 1379 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Catalyst Pharmaceuticals has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Catalyst Pharmaceuticals' Cash Ratio compare to PBLS and ELVN?
According to the Biotechnology industry distribution chart, Catalyst Pharmaceuticals ranks #452 out of 1379 companies for Cash Ratio. This puts Catalyst Pharmaceuticals in the upper half of its industry. The industry median Cash Ratio is 2.97. Catalyst Pharmaceuticals' value of 5.71 is 92.3% above this benchmark. Historically, Catalyst Pharmaceuticals' own Cash Ratio has ranged from 1.81 to 28.54 over the past decade. While the company's 10-year median is 5.75 vs. the industry median of 2.97, Catalyst Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.97, based on 1,379 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Catalyst Pharmaceuticals's current Cash Ratio of 5.71 is 92.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Catalyst Pharmaceuticals and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Catalyst Pharmaceuticals's current Cash Ratio is 5.71, which is near median its own 10-year median of 5.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catalyst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals (CPRX) is currently considered Modestly Overvalued. The stock's GF Value™ is $25.01, compared to a current price of $31.49 — trading 25.9% above its estimated fair value. The current Cash Ratio is 5.71, which is near median its 10-year median of 5.75 and 92.3% above the Biotechnology industry median of 2.97. Catalyst Pharmaceuticals' overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Catalyst Pharmaceuticals (CPRX), the current Cash Ratio is 5.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Catalyst Pharmaceuticals (CPRX) Overvalued in 2026?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals stock appears to be overvalued.
The current stock price of $31.49 is trading 25.9% above its estimated GF Value™ of $25.01.
GuruFocus considers Catalyst Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for CPRX:
Cash Ratio: 5.71 (near median its 10-year median of 5.75)
GF Value™: $25.01 vs. price of $31.49 (25.9% above fair value)
Industry Position: 92.3% above the Biotechnology median (#452 of 1379)
No single metric tells the full story. See the CPRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
70GF Score
Get the complete analysis for CPRX
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPRX has been successfully added to your 
